Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab

Massimo Gentile; Enrica Antonia Martino; Andrea Visentin; Marta Coscia; Gianluigi Reda; Paolo Sportoletti; Francesca Romana Mauro; Luca Laurenti; Marzia Varettoni; Roberta Murru; Annalisa Chiarenza; Ernesto Vigna; Francesco Mendicino; Eugenio Lucia; Sabrina Bossio; Anna Grazia Recchia; Riccardo Moia; Daniela Pietrasanta; Giacomo Loseto; Ugo Consoli; Ilaria Scortechini; Francesca Maria Rossi; Antonella Zucchetto; Hamdi Al-Janazreh; Candida Vitale; Giovanni Tripepi; Graziella D’Arrigo; Ilaria Angeletti; Riccardo Bomben; Antonino Neri; Giovanna Cutrona; Gilberto Fronza; Francesco Di Raimondo; Gianluca Gaidano; Antonio Cuneo; Robin Foà; Manlio Ferrarini; Livio Trentin; Valter Gattei; Fortunato Morabito

doi:10.1038/s41408-020-00358-3

Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab

Massimo Gentile
, Enrica Antonia Martino
, Andrea Visentin
, Marta Coscia
, Gianluigi Reda
, Paolo Sportoletti
, Francesca Romana Mauro
, Luca Laurenti
, Marzia Varettoni
, Roberta Murru
, Annalisa Chiarenza
, Ernesto Vigna
, Francesco Mendicino
, Eugenio Lucia
, Sabrina Bossio
, Anna Grazia Recchia
, Riccardo Moia
, Daniela Pietrasanta
, Giacomo Loseto
, Ugo Consoli

Ilaria Scortechini, Francesca Maria Rossi, Antonella Zucchetto, Hamdi Al-Janazreh, Candida Vitale, Giovanni Tripepi, Graziella D’Arrigo, Ilaria Angeletti, Riccardo Bomben, Antonino Neri, Giovanna Cutrona, Gilberto Fronza, Francesco Di Raimondo, Gianluca Gaidano, Antonio Cuneo, Robin Foà, Manlio Ferrarini, Livio Trentin, Valter Gattei, Fortunato Morabito

Department of Translational Medicine

Research output: Contribution to journal › Letter › peer-review

Original language	English
Article number	92
Journal	Blood Cancer Journal
Volume	10
Issue number	9
DOIs	https://doi.org/10.1038/s41408-020-00358-3
Publication status	Published - 1 Sept 2020

Access to Document

10.1038/s41408-020-00358-3

Cite this

Gentile, M., Martino, E. A., Visentin, A., Coscia, M., Reda, G., Sportoletti, P., Mauro, F. R., Laurenti, L., Varettoni, M., Murru, R., Chiarenza, A., Vigna, E., Mendicino, F., Lucia, E., Bossio, S., Recchia, A. G., Moia, R., Pietrasanta, D., Loseto, G., ... Morabito, F. (2020). Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab. Blood Cancer Journal, 10(9), Article 92. https://doi.org/10.1038/s41408-020-00358-3

@article{d8e6b0d0557e4d6e822293e28aded861,

title = "Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab",

author = "Massimo Gentile and Martino, \{Enrica Antonia\} and Andrea Visentin and Marta Coscia and Gianluigi Reda and Paolo Sportoletti and Mauro, \{Francesca Romana\} and Luca Laurenti and Marzia Varettoni and Roberta Murru and Annalisa Chiarenza and Ernesto Vigna and Francesco Mendicino and Eugenio Lucia and Sabrina Bossio and Recchia, \{Anna Grazia\} and Riccardo Moia and Daniela Pietrasanta and Giacomo Loseto and Ugo Consoli and Ilaria Scortechini and Rossi, \{Francesca Maria\} and Antonella Zucchetto and Hamdi Al-Janazreh and Candida Vitale and Giovanni Tripepi and Graziella D{\textquoteright}Arrigo and Ilaria Angeletti and Riccardo Bomben and Antonino Neri and Giovanna Cutrona and Gilberto Fronza and \{Di Raimondo\}, Francesco and Gianluca Gaidano and Antonio Cuneo and Robin Fo{\`a} and Manlio Ferrarini and Livio Trentin and Valter Gattei and Fortunato Morabito",

note = "Funding Information: Associazione Italiana Ricerca sul Cancro (AIRC) Grant 5× mille no. 9980 (to F.M., M.F., and A.N.), AIRC and Fondazione CaRiCal cofinanced Multi-Unit Regional Grant 2014 no. 16695 (to F.M.) Associazione Italiana Ricerca Cancro (AIRC), Investigator Grant IG-21687 (to V.G.), IG-14326 (to M.F.), Progetto Ricerca Finalizzata PE-2016-02362756 (to V.G.) and RF-2018-12365790 (to A.Z.), Ministero della Salute, Rome, Italy, Progetto Ricerca Finalizzata PE 2016-02362756, Ministero della Salute, Rome, Italy (to V.G.), and by the Italian Ministry of Health 5×1000 funds 2015 and 2016 and Current Research 2016 (to G.C.). Funding of the project was provided by an unrestricted contribution from GILEAD Sciences Srl. The funding sources had no role in identifying statements, abstracting data, synthesizing the results, grading evidence, or preparing the paper, or in the decision to submit the paper for publication (ISR-17-10250).",

year = "2020",

month = sep,

day = "1",

doi = "10.1038/s41408-020-00358-3",

language = "English",

volume = "10",

journal = "Blood Cancer Journal",

issn = "2044-5385",

publisher = "Springer Nature",

number = "9",

}

Gentile, M, Martino, EA, Visentin, A, Coscia, M, Reda, G, Sportoletti, P, Mauro, FR, Laurenti, L, Varettoni, M, Murru, R, Chiarenza, A, Vigna, E, Mendicino, F, Lucia, E, Bossio, S, Recchia, AG, Moia, R, Pietrasanta, D, Loseto, G, Consoli, U, Scortechini, I, Rossi, FM, Zucchetto, A, Al-Janazreh, H, Vitale, C, Tripepi, G, D’Arrigo, G, Angeletti, I, Bomben, R, Neri, A, Cutrona, G, Fronza, G, Di Raimondo, F, Gaidano, G, Cuneo, A, Foà, R, Ferrarini, M, Trentin, L, Gattei, V & Morabito, F 2020, 'Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab', Blood Cancer Journal, vol. 10, no. 9, 92. https://doi.org/10.1038/s41408-020-00358-3

TY - JOUR

T1 - Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab

AU - Gentile, Massimo

AU - Martino, Enrica Antonia

AU - Visentin, Andrea

AU - Coscia, Marta

AU - Reda, Gianluigi

AU - Sportoletti, Paolo

AU - Mauro, Francesca Romana

AU - Laurenti, Luca

AU - Varettoni, Marzia

AU - Murru, Roberta

AU - Chiarenza, Annalisa

AU - Vigna, Ernesto

AU - Mendicino, Francesco

AU - Lucia, Eugenio

AU - Bossio, Sabrina

AU - Recchia, Anna Grazia

AU - Moia, Riccardo

AU - Pietrasanta, Daniela

AU - Loseto, Giacomo

AU - Consoli, Ugo

AU - Scortechini, Ilaria

AU - Rossi, Francesca Maria

AU - Zucchetto, Antonella

AU - Al-Janazreh, Hamdi

AU - Vitale, Candida

AU - Tripepi, Giovanni

AU - D’Arrigo, Graziella

AU - Angeletti, Ilaria

AU - Bomben, Riccardo

AU - Neri, Antonino

AU - Cutrona, Giovanna

AU - Fronza, Gilberto

AU - Di Raimondo, Francesco

AU - Gaidano, Gianluca

AU - Cuneo, Antonio

AU - Foà, Robin

AU - Ferrarini, Manlio

AU - Trentin, Livio

AU - Gattei, Valter

AU - Morabito, Fortunato

N1 - Funding Information: Associazione Italiana Ricerca sul Cancro (AIRC) Grant 5× mille no. 9980 (to F.M., M.F., and A.N.), AIRC and Fondazione CaRiCal cofinanced Multi-Unit Regional Grant 2014 no. 16695 (to F.M.) Associazione Italiana Ricerca Cancro (AIRC), Investigator Grant IG-21687 (to V.G.), IG-14326 (to M.F.), Progetto Ricerca Finalizzata PE-2016-02362756 (to V.G.) and RF-2018-12365790 (to A.Z.), Ministero della Salute, Rome, Italy, Progetto Ricerca Finalizzata PE 2016-02362756, Ministero della Salute, Rome, Italy (to V.G.), and by the Italian Ministry of Health 5×1000 funds 2015 and 2016 and Current Research 2016 (to G.C.). Funding of the project was provided by an unrestricted contribution from GILEAD Sciences Srl. The funding sources had no role in identifying statements, abstracting data, synthesizing the results, grading evidence, or preparing the paper, or in the decision to submit the paper for publication (ISR-17-10250).

PY - 2020/9/1

Y1 - 2020/9/1

UR - https://www.scopus.com/pages/publications/85091129141

U2 - 10.1038/s41408-020-00358-3

DO - 10.1038/s41408-020-00358-3

M3 - Letter

SN - 2044-5385

VL - 10

JO - Blood Cancer Journal

JF - Blood Cancer Journal

IS - 9

M1 - 92

ER -

Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab

Access to Document

Other files and links

Cite this